(Q35148795)

6 August 2017

1 reference

title

Metastatic colorectal cancer: systemic treatment in the new millennium (English)

1 reference

6 August 2017

1 reference

metastatic colon cancer

1 reference

1 reference

Anelisa K Coutinho

1

1 reference

6 August 2017

Caio M Rocha Lima

series ordinal

2

1 reference

6 August 2017

language of work or name

1 reference

1 May 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

10

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

224-238

1 reference

6 August 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Irinotecan in the treatment of colorectal cancer: clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Oxaliplatin: a review of its use in the management of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Oral fluoropyrimidines: a closer look at their toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

New chemotherapy approaches in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Surgical Treatment of Hepatic Metastases From Colorectal Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Treatment of colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Epidermal growth factor receptor dependence in human tumors: more than just expression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Why the epidermal growth factor receptor? The rationale for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

COX-2 is expressed in human pulmonary, colonic, and mammary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

Predictive and prognostic markers in gastrointestinal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000306

10.1177/107327480301000306

21 January 2018

Identifiers

DOI

0 references

1 reference